Sutro Biopharma, Inc. (STRO) Tops Q2 EPS by 9c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q2 EPS of ($0.64), $0.09 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $12.56 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Citigroup (C) Tops Q2 EPS by 42c
• Citi opens 90-day upside catalyst watch on Full Truck Alliance
• UBS Reiterates Neutral Rating on Wingstop (WING), Expects Q2 to Reflect Pressured Sales Trends